John Livingstone is a nationally recognized first-chair trial lawyer focusing on complex pharmaceutical, chemical, and biotechnology patent litigation before U.S. district courts, the U.S. International Trade Commission and the U.S. Court of Appeals for the Federal Circuit. He also serves as lead counsel in post-grant proceedings before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office. John was resident in Finnegan’s Tokyo office, the managing partner of the firm’s Atlanta office, and currently sits on the firm’s Management and VISION Committees.
John has represented innovative pharmaceutical companies in litigation, PTAB, and Federal Circuit matters involving blockbuster drugs such as Zolgensma® (rAAV gene therapy), Kisqali®, Jublia®, Crestor®, Doribax®, Onglyza®, Kombiglyze® XR, Farxiga®, and district court and ITC litigation, PTAB proceedings, and Federal Circuit appeals related to genetically modified microorganisms. He also led the litigation teams responsible for the firm’s appellate victory in Kaken Pharmaceutical Co., Ltd.; Bausch Health Care v. Andrei Iancu and district court win in AstraZeneca AB v. Aurobindo Ltd et al., both of which were selected as Impact Cases of the Year at the LMG Life Sciences Awards.
John routinely lectures about patent law, including as an adjunct professor at Emory University School of Law teaching a course on patent litigation. He has written numerous legal and scientific articles and presents to national and international audiences. John has been recognized by multiple industry organizations and award programs for his excellence in intellectual property law. His honors include consistent recognition as a top IP practitioner in Georgia, accolades for patent litigation and portfolio strategy, and distinction as a leading figure in Hatch-Waxman litigation and life sciences patent disputes.
Updated Oct 2025
